Antifibrotic therapy for fibrotic lung disease beyond idiopathic pulmonary fibrosis
Two antifibrotic medications (nintedanib and pirfenidone) were recommended (conditionally) for the treatment of patients with idiopathic pulmonary fibrosis (IPF) in the 2015 IPF evidence-based guidelines. These medications have been shown to reduce the rate of decline in forced vital capacity among...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
European Respiratory Society
2019-10-01
|
| Series: | European Respiratory Review |
| Online Access: | http://err.ersjournals.com/content/28/153/190022.full |